# Alpha-9 Oncology

> Alpha-9 Oncology is a clinical-stage radiopharmaceutical company engineering bespoke, tumor-targeting molecules that deliver alpha- and beta-emitting isotopes directly to cancer cells while sparing healthy tissue. Spun out of the University of British Columbia and BC Cancer in 2019 and now headquartered in Boston with research operations in Vancouver, the company iteratively optimizes each part of a radiopharmaceutical - binder, linker, chelator and radioisotope - to build a pipeline of paired imaging and therapy candidates. Backed by $258M in total funding, including a $175M Series C in 2024, Alpha-9 aims to expand precision radiotherapy across validated oncology targets.

- **Founded:** 2019
- **Headquarters:** Boston, Massachusetts, United States
- **Founders:** François Bénard (Co-Founder (radiopharmaceutical development, BC Cancer)), Kuo-Shyan Lin (Co-Founder (Head of BC Cancer Radiochemistry Program)), David Perrin (Co-Founder (Professor of Chemistry, UBC))
- **Team size:** ~32 employees
- **Products:** A9-3408, A9-3202, Bespoke radiopharmaceutical platform, Theranostic pairs
- **Notable:** Raised an oversubscribed $175M Series C in October 2024, one of the larger private radiopharma rounds of the year., Grew from a UBC/BC Cancer academic spin-out (2019) to ~$258M total funding., Advanced multiple candidates into the clinic, including imaging agent A9-3202 and Actinium-225 therapeutic A9-3408 (Phase 1).

## Products & services

- **A9-3408** — Actinium-225-based targeted radiotherapeutic candidate in Phase 1 clinical development.
- **A9-3202** — Targeted imaging (diagnostic) agent that has entered clinical trials, used to identify and confirm patients for matched therapy.
- **Bespoke radiopharmaceutical platform** — An iterative discovery engine that independently optimizes each part of a radiopharmaceutical - binder, linker, chelator, and radioisotope - to maximize tumor uptake and minimize off-target toxicity.
- **Theranostic pairs** — Matched diagnostic-and-therapeutic molecule pairs enabling image-then-treat precision oncology.

## Achievements

- Raised an oversubscribed $175M Series C in October 2024, one of the larger private radiopharma rounds of the year.
- Grew from a UBC/BC Cancer academic spin-out (2019) to ~$258M total funding.
- Advanced multiple candidates into the clinic, including imaging agent A9-3202 and Actinium-225 therapeutic A9-3408 (Phase 1).
- Secured long-term supply of two of the scarcest therapeutic isotopes (Ac-225 and n.c.a. Lu-177) through ITM and NorthStar agreements.
- Built a proprietary bespoke platform that independently optimizes binder, linker, chelator, and radioisotope.
- Attracted a top-tier investor syndicate including Lightspeed, a16z Bio + Health, General Catalyst, and RA Capital.

## Latest updates

- **2025-11** — Paul Blanchfield appointed Chief Executive Officer of Alpha-9 Oncology.
- **2024-10** — Closed an oversubscribed $175M Series C led by Lightspeed Venture Partners and Ascenta Capital to advance the clinical pipeline.
- **2024-02** — Announced global master clinical supply agreement with ITM for non-carrier-added Lutetium-177.

## Links

- Website: https://a9oncology.com
- LinkedIn: https://www.linkedin.com/company/a9oncology

---

Profile page: https://yespress.io/alpha-9-oncology
Published by YesPress — https://yespress.io
Last updated: 2026-07-22